Erschienen in:
01.02.2013 | Original Paper
CHADS2 and CHA2DS2-VASc score of patients with atrial fibrillation or flutter and newly detected left atrial thrombus
verfasst von:
Kristina Wasmer, Julia Köbe, Dirk Dechering, Peter Milberg, Christian Pott, Julia Vogler, Jörg Stypmann, Johannes Waltenberger, Gerold Mönnig, Günter Breithardt, Lars Eckardt
Erschienen in:
Clinical Research in Cardiology
|
Ausgabe 2/2013
Einloggen, um Zugang zu erhalten
Abstract
Background
The risk of developing a stroke or systemic embolus due to a left atrial (LA) thrombus in patients with atrial fibrillation (AF) and/or atrial flutter (AFL) is estimated by the CHADS2 score and more recently the CHA2DS2-VASc score. We aimed to further characterize AF/AFL patients who were found to have a LA thrombus on a transesophageal echocardiogram (TEE).
Methods and results
Of 3,165 TEE between 2005 and 2011 for a broad spectrum of indications, we detected 65 AF patients with LA thrombus (2 %). There were 40 men and 25 women, mean age was 65 ± 13 years (range 36–88 years). Mean CHADS2 score was 1.8 ± 1.1 and mean CHA2DS2-VASc score was 3.0 ± 1.6. 11 patients (17 %) had a CHADS2 score of 0, 12 patients (18 %) of 1, 28 patients (43 %) of 2 and 12 patients (18 %) of 3. Hypertension was the most frequent risk factor (72 %), followed by congestive heart failure (32 %), diabetes (23 %) and age ≥75 years (23 %). Mean difference between CHADS2 and CHA2DS2-VASc was 1.25 ± 0.91. Of the 11 patients (17 %) with a LA thrombus despite a CHADS2 score of 0, five had a CHA2DS2-VASc score of 0, four a CHA2DS2-VASc score of 1 and two a CHA2DS2-VASc score of 2.
Conclusion
In an unselected TEE population with newly detected LA thrombus about one-third of patients fell into the low-risk group when classified based on the CHADS2 score, while a much lower population fell in the same low-risk group when classified according to the CHA2DS2-VASc score. However, this does not prove clinical superiority of the CHA2DS2-VASc score over the established CHADS2 score. Whether our observation has clinical implications (e.g. TEE prior to LA ablation irrespective of CHADS2 score), or argues for use of the CHA2DS2-VASc score needs to be evaluated in prospective studies.